In a report published Friday, Jefferies & Company reiterated its Buy rating on Edwards Lifesciences Corp. EW, and raised its price target from $115.00 to $125.00.
Jefferies noted, “We published two physician surveys on transcatheter aortic valve replacement (TAVR), one of early adopters and the other of current non-users. Based on the results, which show strong and sustainable procedure growth, we are increasing our forecasts and target. We continue to rate EW shares Buy.”
Edwards Lifesciences Corp. closed on Thursday at $102.88.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in